CidVion

Celvion Therapeutics is a Cambridge-based biotechnology company focused on developing next-generation combination therapies for solid tumors. The company utilizes its proprietary AI-powered platform, EMphora, to predict and design target combinations that address tumor heterogeneity and escape mechanisms. Celvion's primary technological innovation involves integrating dual T cell receptor (TCR) and chimeric antigen receptor (CAR) systems into a single T cell therapy to target both intracellular and surface antigens. Founded in 2025, the company aims to transform the treatment paradigm for difficult-to-treat cancers like non-small cell lung cancer by leveraging clinical outcome data to prioritize translational signals.